All News
Filter News
Found 65 articles
-
Cell And Gene Therapy Manufacturing Market Size to Worth Around US$ 67.4 Bn by 2030
6/1/2022
The global cell and gene therapy manufacturing market size is expected to be worth around US$ 67.4 billion by 2030, according to a new report by Vision Research Reports.
-
Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis
5/10/2022
Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (MG) today at the 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders.
-
Pharmaceutical Robots Market To Bag US$250.46 Mn By 2026, Large-scale Use in Scientific Research Propels Market Growth
4/22/2022
Albany NY, United States: The global pharmaceutical robots market is predicted in a report by Transparency Market Research to witness high adoption of regional expansion, new product development, and merger and acquisition as key business strategies.
-
Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma
1/25/2022
Cartesian Therapeutics today announced that it has dosed the first patient in a Phase 1/2a multicenter clinical study evaluating Descartes-25 in patients with multiple myeloma.
-
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
-
Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors
12/14/2021
Cartesian Therapeutics today announced the appointment of five internationally recognized Senior Advisors to support its growing clinical pipeline for autoimmune, respiratory, and inflammatory diseases.
-
Cartesian’s Descartes-08 is a new chimeric antigen receptor (CAR) - T cell therapy that strives to target the myasthenia gravis disease at its source.
-
BioSpace Movers & Shakers, Oct. 1
10/1/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
9/28/2021
Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the hire of Miloš Miljković, M.D., as Vice President and Chief Medical Officer.
-
Clinical Catch-Up: August 23-27
8/30/2021
It was a busy week for clinical trial news. Here’s a look. -
Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis
8/24/2021
Cartesian Therapeutics today announced clinical data from the first cohort of an ongoing Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (gMG). Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA).
-
Pharmaceutical Robots Market: Rising Need for Automation in Healthcare Industries to Boost Growth of the Market
5/20/2021
The global pharmaceutical robots market is predicted in a report by Transparency Market Research to witness high adoption of regional expansion, new product development, and merger and acquisition as key business strategies.
-
Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies
5/4/2021
Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced a $2 million competitive R&D award from the National Heart Lung and Blood Institute
-
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.
3/22/2021
Prior to completion of the Arrangement, iCo, which is formed under the Business Corporations Act (British Columbia) is expected to continue under the CBCA and the Resulting Issuer will exist as a CBCA corporation.
-
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
2/22/2021
Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering mRNA-engineered cell therapy in and beyond oncology, today announced that it has initiated a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11,
-
NuTec Employs Epson Cleanroom SCARA Robots to Automate Medical Syringe Manufacturing, Including a COVID-19 Medical Application
2/17/2021
NuTec's Syringe Coating Machine Includes Four Epson G6 Cleanroom SCARA Robots to Precisely, Efficiently, and Cost-Effectively Automate Syringe Manufacturing
-
RNA based Therapeutics and Vaccines Market - Development of COVID-19 Vaccines to Keep Growth Engine Chugging
9/29/2020
The growing prevalence of infectious diseases and cancer across the globe is stated to bring extensive growth opportunities for the global RNA based therapeutics and vaccines market through the assessment period of 2019-2029.
-
Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19
9/1/2020
Descartes-30 engineered to express a unique combination of DNases to eliminate neutrophil extracellular traps (NETs), a key driver of inflammation and clotting in ARDS.
-
Pharmaceutical Robots Market: Large-scale Use of Pharmaceutical Robots in Scientific Research Propels Growth
6/26/2020
The global pharmaceutical robots market is predicted in a report by Transparency Market Research to witness high adoption of regional expansion, new product development, and merger and acquisition as key business strategies.
-
Maryland Booms in the BioCapital Hotbed
3/10/2020
As the BioCapital Hotbed continues to grow, the state of Maryland is seeing a boom in life sciences employment as multiple companies build out manufacturing facilities in the state.